tbuckley/cabot-search huggingface dataset:
Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.
Authors: Celestia S. Higano, A. Oliver Sartor, Nicholas J. Vogelzang, Shaker R. Dakhil, Raoul S. Concepcion, Christopher Michael Pieczonka, Jeffrey L. Vacirca, Ronald F. Tutrone, Carl A. Olsson, David F. Penson, Craig Biggs, Jennifer Susan LIll, Todd E. Gray, Candice McCoy, Matthew R. Cooperberg, Andrew J. Armstrong
Journal: Journal of Clinical Oncology (2015)

e16027 Background: Sip-T is an autologous cellular immunotherapy approved for patients (pts) with metastatic castration-resistant prostate cancer, and no or minimal symptoms. Pts undergo leukapheresis (LP), the peripheral blood mononuclear cells are cultured with PA2024, the immunizing antigen for sip-T, and the final product is infused 3–4 d after LP. This process is repeated every 2 wks for a total of 3 infs, a complete course, over ~1 month. We sought to describe the metrics of sip-T manufacture and inf completion in PROCEED (NCT01306890), a phase 4 registry evaluating men receiving sip-T in the US. Methods: PROCEED pts who received at least 1 sip-T inf were evaluated for number of infs, time between infs, reasons for delay or noninf, and baseline characteristics. Results: Of the pts who had ≥ 1 inf, 1812 (95.3%) of the 1902 pts received all 3 sip-T infs. 1256 pts (69.3%) received all sip-T infs according to the recommended schedule (in 4 wks ± 3 d), 83 pts (4.6%) in <4 wks (1.8% in 2 wks ± 3 d and 2.8% in 3 wks ± 3 d), and 473 pts (26.1%) in ≥ 4.7 wks. Two-percent (114/5698) of sip-T preparations were not infused: 28 (25%) due to total nucleated cell count, antigen-presenting cell [APC] count or APC activation outside specification, 20 (18%) due to pt inability to undergo or complete LP, 16 (14%) not passing sterility requirements, 14 (12%) where the manufacturing process could not be completed, and 14 other (12%). As a group, the pts who did not receive 3 sip-T infs had worse baseline disease characteristics (Table) compared with pts receiving all 3 infs. Conclusions: Over 95% of pts treated with sip-T in the PROCEED registry completed all 3 infs, with the majority at the recommended 2-wk intervals. The ~5% of pts who did not complete the full course had baseline characteristics suggesting more advanced disease. These data suggest that pts with less advanced disease will be able to complete the full course of sip-T per the regimen from the phase 3 IMPACT trial. Clinical trial information: NCT01306890.Patient characteristics. Characteristic, median (range) 3 sip-T infs (n=1812) <3 sip-T infs (n=90) Prostate specific antigen, ng/mL 14 (0–7497) 63 (0.3–5692) Alkaline phosphatase, U/L 82 (0.6–2900) 125 (38–1113) Lactate dehydrogenase, U/L 185 (64–3531) 252 (138–3141)
TCT-420 The fluoroscopy time, door to balloon time, contrast volume use and prevalence of vascular access site failure with transradial versus transfemoral approach in ST segment elevation myocardial infarction: A meta-analysis
Authors: Sukhchain Singh, Mukesh Singh, Jagroop Singh, Navsheen Grewal, Sandeep Khosla
Journal: Journal of the American College of Cardiology (2015)
Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments
Authors: Suzanne Wait, Emily Kell, Saeed Hamid, David H Muljono, Jose Sollano, Rosmawati Mohamed, Samir Shah, None Mamun-Al-Mahtab, Zaigham Abbas, Jennifer Johnston, Tawesak Tanwandee, Jack Wallace
Journal: The Lancet. Gastroenterology & hepatology (2016)
Comprehensive characterization of VISTA expression in patients with acute myeloid leukemia.
Authors: Adam Lamble, Yoko Kosaka, Fei Huang, Kate Sasser, Cristina Tognon, Ted Laderas, Shannon McWeeney, Marc Loriaux, Brian J. Druker, Jeffrey Tyner, Evan Lind
Journal: Journal of Clinical Oncology (2016)

e14546 Background: Acute myeloid leukemia (AML) is a candidate for novel therapeutics, specifically immune checkpoint (IC) inhibitors. V-domain Ig Suppressor of T cell Activation (VISTA) is a novel IC previously shown to be present on hematologic cells and inhibitory towards T cells. VISTA’s role within AML has yet to be defined. We performed detailed studies to characterize VISTA expression of lymphoid cell subsets in patients with AML. Additionally, we assessed the impact of VISTA blockade on the functional capacity of T cells resident in AML bone marrow. Methods: Immunophenotyping was performed on mononuclear cells from primary AML patient specimens using mass cytometry (CyTOF) by staining samples with two panels containing 32 antibodies to surface markers and cytokines. T cells, and their subsets (naïve, central memory, effector memory, effector memory CD45RA+, T regulatory) were defined by the presence or absence of specific surface markers. Functional assays measured both the proliferative capacity and cytokine production profile of bone marrow T cells in response to CD3 stimulation and VISTA blockade in the context of the tumor microenvironment. Results: 10 bone marrow samples from patients with newly diagnosed AML were compared to 5 bone marrow samples from healthy donors. Proportion of T cells and their subsets were similar between patient groups, except T regulatory cells, which represented a higher percentage of mononuclear cells in patients with AML. A higher percentage of T cells within the AML samples expressed VISTA when compared to the healthy donor samples (26% vs 11%, p < 0.05). A higher percentage of AML blasts expressed VISTA when compared to other checkpoint receptor ligands (CD80, CD86, and PD-L1). In both patients with AML and healthy donors, there was minimal proliferation and cytokine production in the setting of VISTA blockade. One patient with AML produced marked elevations of both GM-CSF and M-CSF with VISTA blockade. Conclusions: More T cells express VISTA in patients with AML than healthy donors. VISTA is more highly expressed on AML blasts than other checkpoint ligands. VISTA blockade does not appear to alter T cell proliferation but can affect cytokine production in a subset of patients.
Pegfilgrastim in Congenital Neutropenia: An Observational Survey from the French SCN Registry.
Authors: B. Beaupain, T. Leblanc, O. Reman, J.P. Vannier, O. Hermine, F. Suarez, Y. Bertrand, C. Bellannre-Chantelot, Jean Donadieu
Journal: Blood (2007)
Establishing the role of BPAG1-e in hemidesmosomal integrity and keratinocyte cell biology
Authors: Magdalene Michael, K. Fong, Joey Lai-Cheong, P. J. Dopping-Hepenstal, L. Liu, Richard Groves, J. E. Mellerio, Madeline Parsons, John McGrath
Journal: British Journal of Dermatology (2011)
Systemic Inflammatory Response Syndrome (SIRS) as Predictor of Severe Sepsis (SS) in Hospitalized Patients (pts) with Hematologic Malignancies.
Authors: Anthony Mato, Barry Fuchs, Daniel Heitjan, Erin Olson, Samantha Jacobs, Rosie Mick, David Zheng, Chaitra Ujjani, Andrea Miltiades, Kelly Fabrega, Alicia Morgans, Martin Carroll, Alison Loren, Selina Luger
Journal: Blood (2007)
GW27-e1192 CB1 receptor attenuate neurons apoptosis to improve the outcome of Win55, 212-2 inducing hypothermia after cardiopulmonary resuscitation in rats
Authors: Song Fengqing, Tao Yu, Xiangshao Fang, Longyuan Jiang, Zitong Huang, Yanfang Zuo, Menghua Chen, Fengqing Song
Journal: Journal of the American College of Cardiology (2016)
Enhancement of Dendritic Cell Therapy for Malignancy by Co-Activation of CD1d Restricted NKT Cells, NK Cells, and Antigen CTL.
Authors: Tomomi Hagi, Vy Truong, Hang-Fai So, Qiao Wang, Jacqueline S. Morley, Mie Nieda, Andrew Nicol
Journal: Blood (2006)
Biological Features and Prognostic Impact of CRLF2 Overexpression In Childhood ALL
Authors: Giovanni Cazzaniga, Elena Vendramini, Chiara Palmi, Daniela Silvestri, Daniela Frison, Giulia Longinotti, Anna Leszl, Grazia Fazio, Emanuela Giarin, Vincenzo Rossi, Silvia Bungaro, Giuseppe Basso, Andrea Biondi, Maria Grazia Valsecchi, Valentino Conter, Truus te Kronnie
Journal: Blood (2010)
Abstract CT207: Phase I dose escalation and pharmokinetic study of 14-O-phosphonooxymethyltriptolide
Authors: Edward Greeno, Erkut Borazanci, Jon Gockerman, Ronald Korn, Ashok Saluja, Daniel Von Hoff
Journal: Cancer Research (2015)

Abstract Introduction: We are conducting a phase I, first-in-human trial of 14-O-phosphonooxymethyltriptolide (Minnelide,) a water-soluble prodrug of triptolide, a diterpene derived from the thunder god vine (tripterygium wilfordii). Triptolide is a potent inhibitor of heat shock protein 70 (HSP70) and pancreatic ductal adenocarcinoma over-expresses HSP70 as a protective mechanism. We have previously shown Minnelide to be effective and well tolerated in preclinical models of pancreatic carcinoma. Methods: The study uses a 3+3 dose escalation scheme, enrolling subjects with gastrointestinal malignancies refractory to standard therapies. The drug is administered as a daily, brief IV infusion for 21 days out of a 28 day cycle. The primary endpoint is toxicity, with secondary endpoints of pharmokinetics and response. Results: To date we have enrolled 27 subjects (17 pancreas, 7 colorectal, 3 other GI) at doses from 0.16 to 0.8 mg/m2, with 24 evaluable for toxicity. The therapy has been generally well tolerated with the only common toxicity being hematologic, but one patient experienced reversible cerebellar dysfunction at the highest dose. Pharmokinetics (n = 21) indicate rapid conversion of Minnelide to triptolide, with all Minnelide cleared within 30 minutes and peak triptolide levels achieved within 5 minutes of completion of infusion. Triptolide was rapidly cleared with a half-life of less than 30 minutes, and complete clearance by 6 hours, except in the patient with cerebellar toxicity who demonstrated delayed clearance of the drug. All subjects, except those in the lowest dose cohort, have had a reduction in HSP70 levels. The 9 patients in the first 3 dose cohorts all progressed by the end of cycle two. Tumor response by PET after cycle 1 (n = 19), shows a partial metabolic response in 36%, and stable metabolic disease in 52%. Response after 2 cycles by RECIST criteria (n = 10) shows a 10% PR (gastric) and 60% SD (5 pancreas, 1 rectal) rate with disease control for up to 6 months. 5 patients remain on study, with ongoing enrollment planned. Conclusions: We have seen promising evidence of significant clinical activity in this group of heavily pretreated patients with refractory GI malignancies. The toxicity profile and optimal dosing of Minnelide are being defined. Citation Format: Edward Greeno, Erkut Borazanci, Jon Gockerman, Ronald Korn, Ashok Saluja, Daniel Von Hoff. Phase I dose escalation and pharmokinetic study of 14-O-phosphonooxymethyltriptolide. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT207. doi:10.1158/1538-7445.AM2015-CT207
TCT-242 Remnant risk of secondary cardiovascular events in stable post-myocardial infarction 1-year survivors
Authors: Sungmin Lim, Kiyuk Chang, Youngkeun Ahn, Ha-Wook Park, Donggyu Moon, Eun Ho Choo, Byung-Hee Hwang, Yoon Seok Koh, Hun Jun Park, Pum Joon Kim, Hee-Yeol Kim, Wook Sung Chung, Myung Ho Jeong, Ki-Bae Seung
Journal: Journal of the American College of Cardiology (2015)
Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.
Authors: Pamela S. Becker, Hagop Kantarjian, Frederick R. Appelbaum, Stephen H. Petersdorf, Barry Storer, Sherry A. Pierce, Jianqin Shan, Paul C. Hendrie, John M. Pagel, Andrei Shustov, Derek L. Stirewalt, Stefan Faderl, Elizabeth Harrington, Elihu H. Estey
Journal: Blood (2010)
Impact on Epidemic Measles of Vaccination Campaigns Triggered by Disease Outbreaks or Serosurveys: A Modeling Study
Authors: Justin Lessler, C. Jessica E. Metcalf, Felicity T. Cutts, Bryan T. Grenfell
Journal: PLoS Medicine (2016)

Routine vaccination supplemented by planned campaigns occurring at 2-5 y intervals is the core of current measles control and elimination efforts. Yet, large, unexpected outbreaks still occur, even when control measures appear effective. Supplementing these activities with mass vaccination campaigns triggered when low levels of measles immunity are observed in a sample of the population (i.e., serosurveys) or incident measles cases occur may provide a way to limit the size of outbreaks.Measles incidence was simulated using stochastic age-structured epidemic models in settings conducive to high or low measles incidence, roughly reflecting demographic contexts and measles vaccination coverage of four heterogeneous countries: Nepal, Niger, Yemen, and Zambia. Uncertainty in underlying vaccination rates was modeled. Scenarios with case- or serosurvey-triggered campaigns reaching 20% of the susceptible population were compared to scenarios without triggered campaigns. The best performing of the tested case-triggered campaigns prevent an average of 28,613 (95% CI 25,722-31,505) cases over 15 y in our highest incidence setting and 599 (95% CI 464-735) cases in the lowest incidence setting. Serosurvey-triggered campaigns can prevent 89,173 (95% CI, 86,768-91,577) and 744 (612-876) cases, respectively, but are triggered yearly in high-incidence settings. Triggered campaigns reduce the highest cumulative incidence seen in simulations by up to 80%. While the scenarios considered in this strategic modeling exercise are reflective of real populations, the exact quantitative interpretation of the results is limited by the simplifications in country structure, vaccination policy, and surveillance system performance. Careful investigation into the cost-effectiveness in different contexts would be essential before moving forward with implementation.Serologically triggered campaigns could help prevent severe epidemics in the face of epidemiological and vaccination uncertainty. Hence, small-scale serology may serve as the basis for effective adaptive public health strategies, although, in high-incidence settings, case-triggered approaches are likely more efficient.
Feasibility of obtaining tissue for fluorescence in situ hybridization(FISH) analysis of Her1 or Her2 in advanced non-small cell lung cancer (NSCLC) patients
Authors: L. Wang, C. Polowy, J. Coon, W. Leslie, I. Stewart, P. Bonomi
Journal: Journal of Clinical Oncology (2004)

7156 Background: Randomized trials which tested newer biologic targeted therapies in unselected NSCLC patients(pts) have produced negative results. Although it is possible that performing tumor molecular profiles may identify pts who are most likely to benefit from specific targeted therapy, it has been argued that it is too difficult to obtain adequate tissue from advanced NSCLC pts. The objective of this study was to determine the feasibility of obtaining tissue to evaluate tumor molecular profiles in NSCLC pts. Methods: Tissue specimens were obtained at initial diagnosis and or at the time of recurrence from 113 cases of advanced NSCLC pts. Specimens from 44 pts who were screened for a prospective phase II trial of trastuzumab and from 69 pts who were treated on a gefitinib Expanded Access trial were submitted for Her1 or Her2 FISH analysis. Results: Among 69 cases treated with gefitinib, the relationship of mode of tissue acquisition with FISH analysis of Her2 was examined. The methods and the number of cases were: FNA (11), FNA/core needle biopsy (10), pleural fluid (11), bronchial washing (1), resected tumor (28), bronchoscopy biopsy (5), mediastinoscopy (3). Overall, FISH analysis was accomplished in 53/69 (77%) specimens. FISH analysis was feasible in 18/33 cytologic specimens and 35/36 surgical specimens (χ2=15.29; p<0.0001). We examined the relationship of tissue acquisition and the performance of FISH for Her2 in 44 patients: FNA (9), FNA/core needle biopsy (2), pleural fluid (2), resected tumor (24), bronchoscopy biopsy (4), mediastinoscopy (3). FISH analysis for Her2 was successfully performed in 34/44 (77%) specimens. FISH analysis was feasible in 5/13 cytologic specimens and 29/31 surgical specimens (χ2=12.84; p=0.0003). Conclusions: Our results suggest that obtaining tissue for FISH analysis can be accomplished in approximately 75% of advanced NSCLC pts. There is a significantly higher percentage of successful FISH analysis in surgical specimens (64/67=95%), suggesting that increased efforts to obtain surgical specimens for performing molecular profiles should be encouraged. No significant financial relationships to disclose.
Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).
Authors: Lewis R. Silverman, David R. McKenzie, Bercedis L. Peterson, Richard M. Stone, Bayard L. Powell, Christy Mayo, Jay T. Backstrom, Richard A. Larson
Journal: Blood (2005)
MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu.
Authors: Roccaro M. Roccaro, Antonio Sacco, Abdel Kareem Azab, Feda Azab, Hai Ngo, Molly R Melhem, Phong Quong, Judith M. Runnels, Kenneth C. Anderson, Irene Ghobrial
Journal: Blood (2009)
Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.
Authors: Asmita Mishra, Jeffrey E Lancet, Najla H Al Ali, Eric Padron, Viet Q. Ho, Bryan J Little, Javier Pinilla-Ibarz, Alan F. List, Rami S. Komrokji
Journal: Blood (2012)
GW27-e0055 Conversion to shockable rhythms and subsequent reception of shocks is not necessarily a positive survival prognosticator in initially non-shockable out-of-hospital cardiac arrest patients
Authors: Yan Xiong, Ruiying Zheng, Shengyuan Luo, Jinli Liao, Wanwan Zhang, Jia Xu, Ahamed H. Idris
Journal: Journal of the American College of Cardiology (2016)
Validation and comparison of imaging-based scores for prediction of early stroke risk after transient ischaemic attack: a pooled analysis of individual-patient data from cohort studies
Authors: Peter J Kelly, Gregory W Albers, Anastasios Chatzikonstantinou, Gian Marco De Marchis, Julia Ferrari, Paul George, Mira Katan, Michael Knoflach, Jong S Kim, Linxin Li, Eun-Jae Lee, Jean-Marc Olivot, Francisco Purroy, Nicolas Raposo, Peter M Rothwell, Vijay K Sharma, Bo Song, Georgios Tsivgoulis, Cathal Walsh, Yuming Xu, Aine Merwick
Journal: The Lancet Neurology (2016)
A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
Authors: Davi d Siegel, Orhan Sezer, Jesus F. San Miguel, Maria-Victoria Mateos, Ian Prosser, Michele Cavo, Muhammad Jalaluddin, Katharine Hazell, Priscille M. Bourquelot, Kenneth C. Anderson
Journal: Blood (2008)
Polynitroxyl Albumin Prevents Vaso-Occlusion in Transgenic Sickle Mice.
Authors: Hemchandra Mahaseth, John D. Belcher, Thomas E. Welch, Khalid M. Sonbol, Paul R. Bowlin, Robert P. Hebbel, Li Ma, Carleton J.C. Hsia, Gregory M. Vercellotti
Journal: Blood (2004)
Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia.
Authors: Konstanze Dohner, Andrea Corbacioglu, Karina Eiwen, Judith Ewert, Stefan Frohling, Lars Bullinger, Juergen Krauter, Brigitte Schlegelberger, Arnold Ganser, Hartmut Dohner, Richard F. Schlenk
Journal: Blood (2007)
Diverse Role of DNA Hypermethylation in Reduced Expression of Tumor Suppressor NR4A3 in Acute Myeloid Leukemia
Authors: Ryo Shimizu, Tomoya Muto, Masahiro Takeuchi, Shuhei Koide, Yuhei Nagao, Chika Kawajiri, Emi Togasaki, Nagisa Hasegawa, Shio Sakai, Yusuke Takeda, Naoya Mimura, Chikako Ohwada, Emiko Sakaida, Tohru Iseki, Koutaro Yokote, Atsushi Iwama, Chiaki Nakaseko
Journal: Blood (2015)
A Humanized Anti-CD30 Monoclonal Antibody, XmAb™2513, with Enhanced In Vitro Potency Against CD30-Positive Lymphomas Mediated by High Affinity Fc-Receptor Binding.
Authors: Philip W. Hammond, Omid Vafa, Jonathan Jacinto, Jost Vielmetter, Sher Karki, Sean Yoder, Greg Lazar, Dinesh Raturi, Mike Mollet, Marie Zhu, Lori Kunkel, David Carmichael
Journal: Blood (2005)
Genetic cause of immune dysregulation — one gene or two?
Authors: Stuart G. Tangye
Journal: Journal of Clinical Investigation (2016)

Some autoimmune disorders are monogenetic diseases; however, clinical manifestations among individuals vary, despite the presence of identical mutations in the disease-causing gene. In this issue of the JCI, Massaad and colleagues characterized a seemingly monogenic autoimmune disorder in a family that was linked to homozygous loss-of-function mutations in the gene encoding the endonuclease Nei endonuclease VIII-like 3 (NEIL3), which has not been previously associated with autoimmunity. The identification of an unrelated healthy individual with the same homozygous mutation spurred more in-depth analysis of the data and revealed the presence of a second mutation in a known autoimmune-associated gene. Animals lacking Neil3 had no overt phenotype, but were predisposed to autoantibody production and nephritis following exposure to the TLR3 ligand poly(I:C). Together, these results support further evaluation of the drivers of autoimmunity in supposedly monogenic disorders.
TCT-28 Treat and Repair Strategies for Adult Patients with Atrial Septal Defect and Severe Pulmonary Atrial Hypertension
Authors: Teiji Akagi, Yasufumi Kijima, Yoichi Takaya, Koji Nakagawa, Shunji Sano, Hiroshi Ito
Journal: Journal of the American College of Cardiology (2015)
Use of ERCC1 gene expression to predict the effectiveness of platin-based therapy in colorectal, ovarian and lung cancer
Authors: A. Omori, A. C. Hoffmann, M. M. Shi, H. J. Lenz, C. O. Michie, C. M. Gourley, J. Cooc, J. S. Clark, K. D. Danenberg, P. V. Danenberg
Journal: Journal of Clinical Oncology (2008)

2541 Background: ERCC1 expression is associated with tumor response, progression free survival and overall survival of cancer patients treated with platin-based therapies. We have determined the optimal cut-point values of ERCC1 gene expression for separating patients with best and worst outcomes from platin-based chemotherapy in 3 different types of cancer. Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples were obtained from 366 patients with NSCLC treated in a multicenter phase III trial. The regimes were docetaxel plus cisplatin or docetaxel plus gemcitabine. An additional 191 FFPE from patients with metastatic colorectal cancer treated with FOLFOX ± PTK/ZK in first- and second-line treatment enrolled in the CONFIRM 1 and CONFIRM 2 studies were analyzed. Further, we examined 145 ovarian cancer patients treated with carboplatin or cisplatin alone or in combination with docetaxel or paclitaxel. FFPE tissues were microdissected and analyzed for ERCC-1 mRNA expression using quantitative real-time RT-PCR. The maximal chi-square method was used to determine optimal cut-point values of ERCC1 gene expressions that best segregated patients into poor- and good-outcome subgroups. Results: In lung cancer, ERCC1 showed a relative range from 0.19 to 8.67 (median 1.56). The cut-point value dividing low- and high- expression was 1.71 (53rd percentile). The low-expression group had a 10% greater objective response rate. In colon cancer the range was 0.34 to 4.66 (median 1.16). The cut-point value that best divided patients into long- and short-term survivors was 1.71 (80th percentile, confirming our earlier results in JCO 2001: 4298–4304). In ovarian cancer, the range of expression was 0.38 to 15.71 (median 2.68) with a cut-point at 4.8 (80th percentile) significantly separating patients for overall and progression-free survival. Conclusions: ERCC1 gene expression is a useful predictor of the effectiveness of platin therapy in a number of cancers with precisely determinable ranges and effectiveness cut-point values. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis, Response Genetics Inc. Novartis, Response Genetics Inc., sanofi-aventis Novartis, Response Genetics Inc. Novartis, sanofi-aventis Novartis